Anti-MDA5-positive dermatomyositis and remission in a single referral centre population
Authors' conclusion
In this single centre, tertiary referral population of anti-MDA5-positive dermatomyositis, ~20% of patients experienced long-term drug-free remission after a median disease duration of 4 years. No clinical or biologic factors were associated with clinical remission.
Study context
- Population
- Adults with anti-MDA5-positive DM seen at the Johns Hopkins Myositis Centre, 2003–202038/52 (73%) women
- Participants
- 52 adults
- Outcome
- Clinical remission: off all immunosuppression >1 year while remaining asymptomatic
Methodological detailsobservational, single-centre, tertiary referral
- Observational
- Single-centre
- Tertiary referral
Main finding
As reported in the abstract
Patients achieving clinical remission
9
18%
Observational data: associations, not effects.
Further findings
ILD (inflammatory or fibrotic changes on high resolution computed tomography (HRCT))
- Patients with ILD
- 42/52, 80%
Pulse-dose methylprednisolone required
- Patients requiring pulse-dose methylprednisolone
- 18/52 (35%)
Time from symptom onset to clinical remission
- Median time to clinical remission
- 4 years
Duration of sustained remission
- Median duration of sustained remission (range 1.4-7.8)
- 3.5 years
Factors associated with remission
- No demographic or disease characteristics were significantly associated with remission
Death
- Patients who died
- 5/52 (10%)
Safety
Spontaneous pneumothorax/pneumomediastinum
- Patients with spontaneous pneumothorax/pneumomediastinum
- 4/52 (8%)
Intubation required
- Patients requiring intubation
- 6/52 (12%)
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →